# Effect of Empagliflozin on Inflammation

> **NCT07292909** · PHASE4 · RECRUITING · sponsor: **Hotel Dieu de France Hospital** · enrollment: 100 (estimated)

## Conditions studied

- CAD - Coronary Artery Disease
- Inflamation
- PCI
- SGLT 2 Inhibitors

## Interventions

- **DRUG:** Empagliflozin (SGLT2i)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07292909
- **Lead sponsor:** Hotel Dieu de France Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07292909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07292909, "Effect of Empagliflozin on Inflammation". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07292909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*